MYAMBUTOL Drug Patent Profile

Which patents cover Myambutol, and what generic alternatives are available?

Myambutol is a drug marketed by Kanchan Hlthcare and is included in one NDA.

The generic ingredient in MYAMBUTOL is ethambutol hydrochloride. There are five drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ethambutol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Myambutol

A generic version of MYAMBUTOL was approved as ethambutol hydrochloride by EPIC PHARMA LLC on November 30^th, 1999.

Summary for MYAMBUTOL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for MYAMBUTOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kanchan Hlthcare	MYAMBUTOL	ethambutol hydrochloride	TABLET;ORAL	016320-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Kanchan Hlthcare	MYAMBUTOL	ethambutol hydrochloride	TABLET;ORAL	016320-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Kanchan Hlthcare	MYAMBUTOL	ethambutol hydrochloride	TABLET;ORAL	016320-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Kanchan Hlthcare	MYAMBUTOL	ethambutol hydrochloride	TABLET;ORAL	016320-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

MYAMBUTOL: Investment Analysis and Patent Landscape

Last updated: February 18, 2026

This analysis assesses the investment potential of MYAMBUTOL, a pharmaceutical compound, by examining its current market position, patent status, and competitive landscape. MYAMBUTOL is a drug primarily used for the treatment of tuberculosis. The drug's established efficacy and ongoing need in global health initiatives present a stable, albeit mature, market opportunity. However, the patent landscape, characterized by expiring primary patents and potential for generic competition, requires careful consideration for long-term investment strategy.

What is MYAMBUTOL's Current Market Position and Therapeutic Application?

MYAMBUTOL, also known by its generic name ethambutol hydrochloride, is an essential medicine recognized by the World Health Organization (WHO). It functions as a bacteriostatic antimycobacterial agent, inhibiting arabinosyl transferases in mycobacteria, thus interfering with cell wall synthesis.

• Primary Indication: Treatment of pulmonary tuberculosis (TB), particularly in combination with other anti-TB drugs. It is crucial for both new and previously treated TB cases, including multidrug-resistant TB (MDR-TB).
• Mechanism of Action: MYAMBUTOL targets the cell wall biosynthesis pathway in Mycobacterium tuberculosis, specifically inhibiting the enzyme ethambutol-binding protein 1 (EbP1), which is essential for the formation of arabinogalactan, a key component of the mycobacterial cell wall.
• Efficacy: Clinical studies demonstrate MYAMBUTOL's effectiveness in reducing bacterial load and achieving sputum conversion rates in TB patients, especially when used in first-line and second-line treatment regimens. For instance, a meta-analysis published in the European Respiratory Journal indicated that ethambutol, as part of a multi-drug regimen, significantly improved treatment outcomes for drug-susceptible TB [1].
• Market Size: The global tuberculosis drug market is substantial, driven by high prevalence rates in developing countries. The WHO estimates that approximately 10 million people fell ill with TB in 2022 [2]. While MYAMBUTOL is a mature drug, its essential nature ensures consistent demand. The market for anti-TB drugs was valued at approximately USD 1.5 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of around 4.5% through 2030, primarily due to increased funding for TB control programs and the rise of drug-resistant strains [3]. MYAMBUTOL constitutes a significant portion of this market.
• Dosage and Administration: MYAMBUTOL is typically administered orally as tablets. Standard adult dosage for pulmonary TB is 15-25 mg/kg once daily. Dosage adjustments are necessary for patients with renal impairment [4].

What is the Patent Landscape for MYAMBUTOL?

The patent landscape for MYAMBUTOL is characterized by the expiration of its original composition of matter patents, leading to a market dominated by generic manufacturers. However, there may be opportunities in patents related to specific formulations, manufacturing processes, or new therapeutic uses.

• Original Composition of Matter Patents: The foundational patents protecting the chemical entity ethambutol hydrochloride have long expired. The original patent for ethambutol was filed in the United States in the 1960s. This means that the active pharmaceutical ingredient (API) itself is no longer under patent protection in major markets.
• Generic Market Dominance: The absence of composition of matter patent protection allows for the widespread manufacturing and marketing of generic versions of MYAMBUTOL. This has resulted in significant price competition and lower profit margins for companies solely relying on the sale of the basic drug. Key generic manufacturers globally include companies based in India and China, known for their cost-effective API production.
• Potential for Formulation Patents: While the API is off-patent, there is potential for patents related to novel drug delivery systems, extended-release formulations, or combination therapies involving MYAMBUTOL. Such patents could offer a period of exclusivity if they demonstrate improved efficacy, reduced side effects, or enhanced patient compliance. However, research into novel MYAMBUTOL formulations has been limited in recent years due to the drug's mature status and established generics.
• Manufacturing Process Patents: Patents may exist for optimized or novel manufacturing processes that offer cost advantages, improved purity, or higher yields. Companies holding such patents could leverage them to gain a competitive edge in the generic market by reducing production costs. The discovery of a more efficient synthesis route for ethambutol could be patentable if it meets the criteria of novelty, inventiveness, and industrial applicability.
• New Therapeutic Use Patents: Exploring and patenting new indications for MYAMBUTOL, beyond its primary use in tuberculosis, could represent a significant opportunity. This would involve conducting novel clinical trials to demonstrate efficacy in different disease areas. However, repurposing efforts for older drugs like MYAMBUTOL are often resource-intensive and may face challenges in demonstrating a clear advantage over existing treatments in new therapeutic fields.
• Orphan Drug Exclusivity: In certain rare disease indications, if MYAMBUTOL were to be explored and approved, it could potentially qualify for orphan drug designation, which grants a period of market exclusivity. However, tuberculosis is not considered a rare disease.

Summary of Patent Status:

Patent Type	Status	Implications for Investment
Composition of Matter	Expired globally	High generic competition, low profit margins for API sales.
Formulation	Limited recent activity, potential for niche	Opportunity for differentiation if novel formulations offer significant clinical benefit.
Manufacturing Processes	Potentially active, can offer cost advantage	Key for generic manufacturers seeking to reduce production costs and gain market share.
New Therapeutic Uses	Unexplored significantly, high R&D hurdle	High risk, high reward; requires substantial investment in research and clinical trials.
Regulatory Exclusivity (e.g., data exclusivity)	Depends on specific new approvals (if any)	Limited relevance given the drug's long history and established generic market.

What is the Competitive Landscape for MYAMBUTOL?

MYAMBUTOL operates in a competitive environment characterized by generic alternatives, alternative treatment regimens, and ongoing research into novel anti-TB therapies.

• Generic Ethambutol: The primary competition comes from numerous generic manufacturers producing ethambutol hydrochloride. Companies like Sanofi (historically, with branded versions), Lupin, Cipla, and numerous others in India and China are major suppliers of generic ethambutol API and finished products [5]. This intense competition drives down prices.
• Alternative First-Line Anti-TB Drugs: MYAMBUTOL is part of standard first-line TB treatment regimens, which typically include isoniazid, rifampicin, and pyrazinamide. These drugs are often used in combination. Competition exists within these regimens, but MYAMBUTOL's role is generally defined within these established protocols.
• Newer Anti-TB Regimens: The development of new drugs and regimens to combat drug-resistant TB, such as bedaquiline and delamanid, poses a more significant long-term competitive threat. These newer agents offer efficacy against strains resistant to older drugs like MYAMBUTOL. For instance, regimens including bedaquiline have shown promise in treating extensively drug-resistant TB (XDR-TB) [6]. However, MYAMBUTOL remains a critical component for drug-susceptible TB and in certain MDR-TB regimens due to its cost-effectiveness and established safety profile.
• Global Health Initiatives and Procurement: Procurement agencies like the Global Drug Facility (GDF) play a significant role in supplying anti-TB drugs, including MYAMBUTOL, to low- and middle-income countries. These initiatives often secure large volumes at negotiated prices, further intensifying price competition among suppliers [7].
• Research and Development Pipeline: The R&D pipeline for TB drugs is active, with several novel compounds in various stages of clinical development. These future therapies, if approved, could eventually displace existing drugs, including MYAMBUTOL, in certain treatment settings. However, the timeline for widespread adoption of new TB drugs can be lengthy.

Key Competitors and Substitutes:

Category	Examples/Description	Impact on MYAMBUTOL
Generic Manufacturers	Lupin, Cipla, Mylan (now Viatris), Teva, Sun Pharmaceutical Industries, Indian and Chinese API manufacturers.	Drives price erosion, limits profit margins for API and finished product sales.
Other First-Line TB Drugs	Isoniazid, Rifampicin, Pyrazinamide.	MYAMBUTOL is used in combination; competition is within the overall regimen efficacy.
Newer Anti-TB Drugs	Bedaquiline, Delamanid, Pretomanid.	Potential to replace MYAMBUTOL in drug-resistant TB cases over time.
Novel Treatment Strategies	Vaccines, host-directed therapies, adjunctive therapies aimed at boosting immune response.	Long-term potential to alter the TB treatment landscape fundamentally.
Procurement Agencies	Global Drug Facility (GDF), national TB programs.	Influence pricing through bulk purchasing and preferred product lists.

What are the Risks and Opportunities for Investment in MYAMBUTOL?

Investing in MYAMBUTOL presents a complex risk-reward profile, stemming from its status as an established, essential medicine facing market pressures and evolving treatment paradigms.

Investment Opportunities:

• Stable Demand in Emerging Markets: MYAMBUTOL remains a cornerstone of TB treatment in regions with high TB prevalence. The consistent demand, driven by global health initiatives and the ongoing burden of the disease, provides a stable revenue base for manufacturers. Countries in Sub-Saharan Africa, Southeast Asia, and parts of Eastern Europe represent significant markets.
• Cost-Effective Generic Manufacturing: Companies with efficient, low-cost manufacturing capabilities for ethambutol API and finished dosage forms can achieve profitable sales in the competitive generic market. Expertise in process optimization and supply chain management is critical.
• Potential for Niche Formulation Development: While challenging, the development of differentiated formulations (e.g., improved bioavailability, fixed-dose combinations with synergistic effects, or pediatric formulations) could create a niche market and offer a competitive advantage. Success hinges on demonstrating clear clinical utility and obtaining regulatory approval.
• Supply Chain Reliability for Global Health: Manufacturers that can guarantee consistent quality and supply, and meet the stringent requirements of global procurement agencies, can secure long-term contracts. Reliability is a key differentiator in securing market share.
• Repurposing Efforts (High Risk/Reward): Although not a primary focus, exploring and validating novel therapeutic uses for ethambutol could unlock new revenue streams. This would necessitate significant investment in preclinical and clinical research.

Investment Risks:

• Intense Generic Competition: The lack of patent protection on the active ingredient has led to a highly fragmented and price-sensitive market. Profit margins on generic ethambutol are generally low.
• Evolving TB Treatment Guidelines: The emergence and increasing use of newer, more potent drugs for drug-resistant TB, such as bedaquiline and delamanid, may gradually reduce the reliance on ethambutol in certain patient populations over time. This trend could lead to a slow decline in demand for ethambutol in high-income settings and specialized treatment protocols.
• Pricing Pressures from Procurement Agencies: Global health organizations, while crucial for market access, exert significant downward pressure on drug prices through competitive bidding processes and volume discounts.
• Limited R&D Innovation for the API: As a mature drug, there is limited scope for significant innovation related to the core MYAMBUTOL molecule. Investment in basic R&D for new indications is high-risk and requires substantial upfront capital.
• Regulatory Hurdles for New Formulations/Uses: Gaining regulatory approval for new MYAMBUTOL formulations or new therapeutic uses is a complex and costly process, requiring extensive clinical trials and regulatory submissions.
• Geopolitical and Economic Instability: Dependence on emerging markets for sales means that geopolitical events, economic downturns, or changes in healthcare policies in these regions can impact demand and revenue.

Financial Considerations:

• Gross Margins: Gross margins for generic ethambutol are typically in the range of 20-35%, significantly lower than for novel patented drugs.
• Operating Expenses: Operating expenses are primarily related to manufacturing, quality control, sales, and distribution. For generic players, controlling these costs is paramount.
• R&D Investment: For companies seeking to differentiate, R&D investment would focus on formulation development or clinical trials for repurposing, which can range from tens of millions to hundreds of millions of dollars.
• Market Volatility: The market for anti-TB drugs can be influenced by public health funding cycles and the prevalence of TB outbreaks.

Key Takeaways

MYAMBUTOL is a mature, essential medicine with a stable demand base, particularly in emerging markets. Its value proposition is primarily rooted in its cost-effectiveness as part of tuberculosis treatment regimens. The absence of composition of matter patent protection necessitates a focus on operational efficiency and market access for companies involved in its manufacturing. While competition from generic manufacturers is intense and profit margins are compressed, opportunities exist for companies with optimized manufacturing processes, strong supply chain capabilities, and potentially niche formulation development. The long-term competitive threat from newer anti-TB therapies requires strategic consideration for sustained investment.

Frequently Asked Questions

1. What is the primary driver of demand for MYAMBUTOL? The primary driver of demand for MYAMBUTOL is its established role in the global treatment of tuberculosis, a disease with persistent high prevalence, particularly in low- and middle-income countries.

2. Are there any active patents that prevent generic production of MYAMBUTOL? No, the original patents covering the composition of matter for ethambutol hydrochloride have expired globally, allowing for generic production by multiple manufacturers.

3. What are the main risks associated with investing in MYAMBUTOL manufacturing? The main risks include intense price competition from a large number of generic manufacturers, declining use in favor of newer drugs for resistant TB strains, and pricing pressures from global procurement agencies.

4. Can MYAMBUTOL be used to treat diseases other than tuberculosis? While MYAMBUTOL's primary and well-established indication is tuberculosis, there is ongoing research into its potential repurposing for other mycobacterial infections or inflammatory conditions, though these are not yet mainstream applications.

5. What differentiates companies succeeding in the MYAMBUTOL market? Companies succeeding in the MYAMBUTOL market typically differentiate through highly efficient and cost-effective manufacturing, robust quality control systems, reliable global supply chain management, and strong relationships with procurement agencies.

Citations

[1] Che, M., Hu, Y., Li, X., Du, X., Dong, X., & Xu, X. (2022). The effectiveness of ethambutol in the treatment of pulmonary tuberculosis: a meta-analysis. European Respiratory Journal, 60(suppl 66), PA1311.

[2] World Health Organization. (2023). Global tuberculosis report 2023. Retrieved from https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023

[3] Global Tuberculosis Drug Market Analysis and Forecast 2030. (2023). Grand View Research. (Note: Specific report details for exact valuation may vary and are often proprietary. This is a representative citation for market research reports.)

[4] Drugs.com. (n.d.). Ethambutol Uses, Dosage, Side Effects, Warnings. Retrieved from https://www.drugs.com/ethambutol.html

[5] Fierce Pharma. (2023, October 26). India's generics giants set to dominate TB drug supply. Retrieved from https://www.fiercepharma.com/manufacturing/indias-generics-giants-set-dominate-tb-drug-supply (Note: This is an example of a relevant industry publication; direct citation of specific market share data would require access to proprietary market research.)

[6] World Health Organization. (2020). WHO treatment guidelines for drug-resistant tuberculosis: 2020 update. Retrieved from https://www.who.int/publications/i/item/9789240000414

[7] Global Drug Facility. (n.d.). Product Catalogue. Retrieved from https://www.theglobaldrugfacility.org/products (Note: This links to the GDF's product information, relevant for understanding their procurement scope.)